BRAF and central nervous system cancer: Following these encouraging data, a phase II randomized study comparing first-line combination dabrafenib plus trametinib (D + T) versus traditional chemotherapeutic agents carboplatin plus vincristine (C + V) in BRAF V600–mutant–positive pediatric glioma patients has been undertaken (NCT02684058) (22).